The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.

Breast Care (Basel) 2012 Feb 20;7(1):25-31. Epub 2012 Feb 20.

OnkoZentrum, Klinik im Park, Zürich, University Hospital of Zürich, Switzerland.

BACKGROUND: The growth inhibitory effect of tamoxifen is used for the treatment of breast cancer. Tamoxifen efficacy is mediated by its biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoenzyme, to the active metabolite endoxifen. We investigated the relationship of CYP2D6 genotypes to the metabolism of dextromethorphan (DM), which is frequently used as a surrogate marker for the formation of endoxifen. METHODS: The CYP2D6 genotype was determined by polymerase chain reaction (PCR) in previously untreated patients with hormone receptor-positive invasive breast cancer considered to receive antihormonal therapy. The DM/dextrorphan (DX) urinary excretion ratios were obtained in a subset of patients by high-pressure liquid chromatography (HPLC)-mediated urine analysis after intake of 25 mg DM. The relationships of genotype and corresponding phenotype were statistically analyzed for association. RESULTS: From 151 patients predicted based on their genotype data for the 'traditional' CYP2D6 phenotype classes poor, intermediate, extensive and ultrarapid, 83 patients were examined for their DM/DX urinary ratios. The genotype-based poor metabolizer status correlated with the DM/DX ratios, whereas the intermediate, extensive and ultrarapid genotypes could not be distinguished based on their phenotype. Citalopram intake did not significantly influence the phenotype. CONCLUSIONS: The DM metabolism can be reliably used to assess the CYP2D6 enzyme activity. The correlation with the genotype can be incomplete and the metabolic ratios do not seem to be compromised by citalopram. DM phenotyping may provide a standardized tool to better assess the CYP2D6 metabolic capacity.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000336551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335358PMC
February 2012
27 Reads

Publication Analysis

Top Keywords

breast cancer
12
intermediate extensive
8
assess cyp2d6
8
extensive ultrarapid
8
cyp2d6
6
phenotype
5
excretion ratios
4
ratios
4
urinary excretion
4
dm/dextrorphan urinary
4
antihormonal therapy
4
intake influence
4
therapy dm/dextrorphan
4
citalopram intake
4
phenotype citalopram
4
based phenotype
4
liquid chromatography
4
distinguished based
4
high-pressure liquid
4
patients high-pressure
4

References

(Supplied by CrossRef)

Brauch H et al.
Clin Chem 2009

Barrière J et al.
Bull Cancer 2010

Jin Y et al.
J Natl Cancer Inst 2005

Stearns V et al.
J Natl Cancer Inst 2003

Johnson MD et al.
Breast Cancer Res Treat 2004

Borges S et al.
Clin Pharmacol Ther 2006

Schroth W et al.
JAMA 2009

Newman WG et al.
Clin Cancer Res 2008

Ramón T et al.
Breast Cancer Res Treat 2010

Bijl MJ et al.
Breast Cancer Res Treat 2009

Okishiro M et al.
Cancer 2009

Similar Publications